Anderson G, Scott M. Determination of product shelf life and activation energy for five drugs of abuse. Clin Chem, 1991; 37(3):398-402. https://doi.org/10.1093/clinchem/37.3.398 |
|
Bajaj S, Singla D, Sakhuja N. Stability testing of pharmaceutical products. J Appl Pharm Sci, 2012; 2(3):129-38. |
|
Barone A. 2020. Bottleneck. [ONLINE] Available at: https:// www.investopedia.com/terms/b/bottleneck.asp [Accessed August 2021] |
|
Borkakoty B, Jakharia A, Bali NK, Sarmah MD, Hazarika R, Baruah G, Bhattacharya C, Biswas D. A preliminary evaluation of normal saline as an alternative to viral transport medium for COVID-19 diagnosis. The Indian journal of medical research, 2021, 153(5&6):684-688. https://doi.org/10.4103/ijmr.IJMR_4346_20 |
|
Brown S, Bessant J. Lamming R. Strategic operations management. 2nd edition, Elsevier Butterworth-Heinemann, Oxford, UK, 2005. |
|
Chan KH, Sridhar S, Zhang RR, Chu H, Fung AYF, Chan G, Chan JFW, To KKW, Hung IFN, Cheng VCC, Yuen KY. Factors affecting stability and infectivity of SARS-CoV-2. |
|
J Hosp Infect, 2020; 106(2):226-31. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. Available via https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/situation-reports/ (Accessed April 2021). |
|
Inactivation Transport Medium (ITM). Product features. Wuxi NEST Biotechnology Co.,Ltd, Jiangsu, China, 2020. Available via https://www. nest-biotech.com/disposable-sampler/59256318.html (Accessed March 2022). |
|
Johnson FB. Transport of viral specimens. Clin Microbiol Rev, 1990; 3(2):120-31. https://doi.org/10.1128/CMR.3.2.120 |
|
Kirkland PD, Frost MJ. The impact of viral transport media on PCR assay results for the detection of nucleic acid from SARS-coV-2. Pathology, 2020; 52(7):808-11. https://doi.org/10.1016/j.pathol.2020.09.013 |
|
Koenig, DT. Manufacturing engineering: principles for optimization. 2nd edition, Taylor & Francis, Washington, DC, 1994. |
|
Lam F, Moubarak M, Wilson J, Ford B. Preparing viral transport media for COVID-19 testing, 2020 [ONLINE]. Available via https://www. pppmag.com/article/2638 (Accessed April 2021). |
|
Luinstra K, Petrich A, Castriciano S, Ackerman M, Chong S, Carruthers S, Ammons B, Mahony JB, Smieja M. Evaluation and clinical validation of an alcohol-based transport medium for preservation and inactivation of respiratory viruses. J Clin Microbiol, 2011; 49(6):2138-42. https://doi.org/10.1128/JCM.00327-11 |
|
McAuley J, Fraser C, Paraskeva E, Trajcevka E, Sait M, Wang N, Bert E, Purcell D, Strugnell R. Optimal preparation of SARS -CoV-2 viral transport medium for culture. Virol J, 2021; 18(53):1-6. https://doi.org/10.1186/s12985-021-01525-z |
|
Monczka RM, Handfield RB, Giunipero LC, Patterson JL. Purchasing and supply chain management. 6th edition, Cencage Learning, Boston, MA, 2016. |
|
Orlicky J. Material requirements planning. McGraw-Hill, New York, 1975. |
|
Petersen J, Dalal S, Jhala D. Criticality of in-house preparation of viral transport medium in times of shortage during COVID-19 pandemic. Lab Med, 2021; 52(2):e39-45. https://doi.org/10.1093/labmed/lmaa099 |
|
Smith KP, Cheng A, Chopelas A, DuBois CS, Mezghani I, Rodriguez S, Talay M, Kirby JE. Large-scale, in house production of viral transport media to support SARS-Cov-2 PCR testing in a multihospital health care network during the COVID-19 pandemic. J Clin Microbiol, 2020; 58(8):1-7. https://doi.org/10.1128/JCM.00913-20 |
|
Rodino KG, Espy MJ, Buckwalter SP, Walchak RC, Germer JJ, Fernholz E, Boerger A, Schuetz AN, Yao JD, Binnicker MJ. Evaluation of saline, phosphate-buffered saline, and minimum essential medium as potential alternatives to viral transport media for SARS-CoV-2 testing. J Clin Microbiol, 2020; 58(6):e00590-20. https://doi.org/10.1128/JCM.00590-20 |
|
Van Bockel D, Munier CML, Turville S, Badman SG, Walker G, Stella AO, Aggarwal A, Yeang M, Condylios A, Kelleher AD, Applegate TL, Vallely A, Whiley D, Rawlinson W, Cunningham P, Kaldor J, Guy R. Evaluation of commercially available viral transport medium (VTM) for SARS-CoV-2 inactivation and use in point-of-care (POC) testing. Viruses, 2020; 12(11):1208. https://doi.org/10.3390/v12111208 |
|
Wingfield PT. Use of protein folding reagents. Curr Protoc Protein Sci, 2001; Appendix 3:Appendix-3A. |
|
World Health Organization. Target product profiles for priority diagnostics to support response to COVID-19 pandemic v.1.0. R&D Blueprint, Switzerland, 2020. |